The University of Chicago Header Logo

Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors.

Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol. 2015 Jul; 16(7):e313.

View in: PubMed